Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy

The results of this study suggest that in patients with NSCLC, the optimal treatment regimen may differ between those with PD-L1 TPS of 1-20% and 21-49%; moreover, nivolumab and ipilimumab-based therapy may be more effective than chemotherapy with a single-agent ICI for treating advanced NSCLC with ultra-low PD-L1 expression, particularly in those with a PD-L1 TPS of 1-20%.

Authors

Takafumi Fukui (ORCID: https://orcid.org/0000-0001-5049-2742)
Motoko Tachihara
Y. Hatakeyama
Masahiro Katsurada (ORCID: https://orcid.org/0000-0003-4655-3367)
Sadaaki Hori
K. Matsumura
Keiko Okuno
Tatsunori Kiriu (ORCID: https://orcid.org/0000-0001-6877-2005)
Sho Yoshimura
Nanako Miwa

Institutions

Kobe Medical Center (JP)
Hyogo Prefectural Awaji Medical Center (JP)
Tokyo Metropolitan Tama-Hokubu Medical Center (JP)
Himeji Medical Center (JP)
Kagawa Prefectural Central Hospital (JP)
Akashi Medical Center (JP)
Takatsuki General Hospital (JP)
Kobe University (JP)

Publication Details

Journal: Anticancer Research
Published: 2025-08-28
DOI: https://doi.org/10.21873/anticanres.17745
Primary Topic: Cancer Immunotherapy and Biomarkers
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy

Takafumi Fukui, Motoko Tachihara, Y. Hatakeyama, Masahiro Katsurada et al.

Aug 28, 2025

Anticancer Research

Cancer Immunotherapy and Biomarkers

article

Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy

Takafumi Fukui, Motoko Tachihara, Y. Hatakeyama, Masahiro Katsurada, Sadaaki Hori, K. Matsumura, Keiko Okuno, Tatsunori Kiriu, Sho Yoshimura, Nanako Miwa

August 28, 2025article en

Abstract

The results of this study suggest that in patients with NSCLC, the optimal treatment regimen may differ between those with PD-L1 TPS of 1-20% and 21-49%; moreover, nivolumab and ipilimumab-based therapy may be more effective than chemotherapy with a single-agent ICI for treating advanced NSCLC with ultra-low PD-L1 expression, particularly in those with a PD-L1 TPS of 1-20%.

Anticancer ResearchVol. 45(9)

Kobe Medical Center (JP), Hyogo Prefectural Awaji Medical Center (JP), Tokyo Metropolitan Tama-Hokubu Medical Center (JP), Himeji Medical Center (JP), Kagawa Prefectural Central Hospital (JP), Akashi Medical Center (JP), Takatsuki General Hospital (JP), Kobe University (JP)

Openalex Percentile: Top 69%

Cancer Immunotherapy and Biomarkers

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Stratification by PD-L1 TPS in Advanced NSCLC With Low PD-L1 Expression for Optimizing Immunotherapy — Takafumi Fukui, Motoko Tachihara, et al. · Anticancer Research (2025) | TGRS Research Map | TGRS